Medindia

X

USFDA Approval Awaited By Glenmark Pharmaceuticals For 4-6 Products During This Year

by Lakshmi Darshini on  August 25, 2015 at 6:40 PM Drug News   - G J E 4
From the US Food and Drug Administration (USFDA) Glenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal, a senior official said.
USFDA Approval Awaited By Glenmark Pharmaceuticals For 4-6 Products During This Year
USFDA Approval Awaited By Glenmark Pharmaceuticals For 4-6 Products During This Year
Advertisement

"We are expecting approvals for 4-6 products from the USFDA during this year," Glenmark Pharmaceuticals President and Head-India Business Sujesh Vasudevan told on the sidelines of launch of Teneligliptin in Telangana. The company had already got approvals for eight products this year, he added.

Advertisement
Teneligliptin, a new third generation oral anti-diabetic agent, is used for the management of Type 2 Diabetes Mellitus. Glenmark has launched this molecule under two brands, Ziten and Zita Plus, at Rs 19.90 per tablet.

"... the launch of these two products will lower the daily cost of treatment for a diabetes patient on Gliptin therapy by approximately 55 percent," Vasudevan said. Glenmark's diabetes segment is valued at around Rs 100 crore, Vasudevan said, adding it is growing at 20 percent per annum.

Reacting to a query, he said, "The capex for this year is Rs 600 crore and majority of this will go for the plant in the US."

Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All

More News on: